Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KLK5
REST API REST API
Homo sapiens
KLK5 is differentially expressed in 141 experiments: 90 organism parts: skin, testis, ... (88 more);, 68 disease states: normal, adenocarcinoma, ... (66 more);, 41 cell types 307 cell lines 20 compound treatments and 58 other conditions.
Synonyms SCTE, KLK-L2
Orthologs KLK5 (Bos taurus)   Klk5 (Mus musculus)   LOC687873 (Rattus norvegicus)   KLK5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, extracellular space, peptidase activity, extracellular region, serine-type peptidase activity, epidermis development, proteolysis, serine-type endopeptidase activity, positive regulation of G-protein coupled receptor protein signaling pathway
InterPro Term Peptidase_S1A, Peptidase_S1_S6
UniProt Accession Q9Y337
Search EB-eye ENSG00000167754
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-7224, E-GEOD-1577, E-MTAB-24, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, E-GEOD-29119, ... (24 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
BT20
2
E-MTAB-37, E-MTAB-62
BT474
2
E-MEXP-440, E-MTAB-62
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC1937
2
E-MTAB-37, E-MTAB-62
HCC1954
2
E-MTAB-37, E-GEOD-29119
301 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-MTAB-24, E-MTAB-25, E-GEOD-29119, ... (20 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
endothelial cell
2
E-GEOD-3920, E-GEOD-3998
cancer cell culture
1
E-GEOD-14990
erythropoietic
1
E-GEOD-9894
plasma cell
1
E-GEOD-6691
leydig cell
1
E-MTAB-25
35 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-10797, E-GEOD-19743, E-GEOD-15960, E-GEOD-3524, ... (22 experiments)

Factor Value U/D Experiments
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
diffuse large B-cell lymphoma
1
E-MTAB-62
no inhalation injury
1
E-GEOD-19743
Duchenne muscular dystrophy
1
1
E-GEOD-3307
Wilms tumor
1
E-GEOD-2712
astrocytoma
1
E-GEOD-4290
62 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-6907, E-GEOD-6462, E-MEXP-941, ... (13 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
heregulin
1
E-GEOD-6462
N-nitrosodimethylamine
1
E-GEOD-6907
estradiol
1
E-GEOD-20081
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
E-GEOD-6932
none
1
E-GEOD-1615
14 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
34 years
1
E-GEOD-4922
34
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-TABM-234, E-GEOD-7967, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-5372, E-GEOD-2034

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-21138

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-20847

Genotype
studied in E-GEOD-17476, E-GEOD-2292, E-TABM-321, E-GEOD-18005, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-22278, E-MEXP-1103

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-19330, E-TABM-666, ... (16 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-1801, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1309, E-GEOD-1657

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-43, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-1561

Tumor size
studied in E-GEOD-3494, E-GEOD-6532

Processing time: 0.45 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM